drugset / Trial / NCT01204099
Study of PX-866 and Docetaxel in Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase 1: To determine the maximally tolerated dose (MTD) or recommended dose (RD) and any potential efficacy of PX-866 in combination with docetaxel in patients with solid tumors. Phase 2: To determine the antitumor activity and safety of PX-866 in combination with docetaxel versus docetaxel alone in patients with NSCLC or SCCHN.
Timeline
- Start
- 2010-09
- Primary completion
- 2013-12
- Completion
- 2014-02